Soleus Capital Management’s Neuropace NPCE Stock Holding History
Bought
Maintained
Sold
Other funds holding NPCE
PCH
FLAM
O
DCM
VCM
AC
Soleus Capital Management's NPCE Position: Q1 2026 in Review
Soleus Capital Management increased its Neuropace (NPCE) stake by 8.5% in Q1 2026, buying an estimated $3.44M and bringing the position to 2,932,207 shares worth $38.6M. The position accounts for 1.56% of the portfolio, ranked #19.
Soleus Capital Management first reported a position in NPCE in Q2 2021 and has held it in 20 quarters since. The position peaked at $41.7M in Q4 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.
- Soleus Capital Management held 2,932,207 shares of Neuropace worth $38.6M as of Q1 2026.
- Soleus Capital Management bought 228,999 Neuropace shares in Q1 2026, an estimated $3.44M.
- Neuropace made up 1.56% of Soleus Capital Management's portfolio in Q1 2026, its #19 holding.
- Soleus Capital Management first reported a position in Neuropace in Q2 2021 and has held it in 20 quarters since.
- Soleus Capital Management's Neuropace position peaked at $41.7M in Q4 2025.
- 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.
Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.